HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
USFDA completes inspection at Morepen Laboratories’ Masulakhanna facility with Zero observations
Apr-17-2026

United States Food and Drug Administration (USFDA) has successfully completed inspection at Morepen Laboratories’ Masulakhanna (HP) facility, with Zero observations (NIL Form 483). This marks the fourth consecutive NIL 483 inspection for Morepen over the past eight years, underscoring the company’s unwavering commitment to global quality and regulatory standards.

The latest inspection outcome reflects Morepen’s robust quality management systems, strong data integrity practices, and deep-rooted culture of regulatory compliance. The company has consistently aligned its operations with evolving global standards, including current ICH and CFR (Part-21) guidelines, ensuring high levels of product quality, safety, and efficacy. 

Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.


  RELATED NEWS >>